Patients with metastatic renal cell carcinoma treated with
cabozantinib in the Czech Republic: analysis of four cancer
centers

J 2022

Patients with metastatic renal cell carcinoma treated with cabozantinib in the Czech Republic: analysis of four cancer centers

RICHTER, Igor, Alexandr POPRACH, Anezka ZEMANKOVA, Tomas BUCHLER, Jiri BARTOS et. al.

Basic information

Original name

Patients with metastatic renal cell carcinoma treated with cabozantinib in the Czech Republic: analysis of four cancer centers

Authors

RICHTER, Igor (203 Czech Republic, guarantor), Alexandr POPRACH (203 Czech Republic, belonging to the institution), Anezka ZEMANKOVA (203 Czech Republic), Tomas BUCHLER (203 Czech Republic), Jiri BARTOS (203 Czech Republic), Vladimir SAMAL (203 Czech Republic), Hana STUDENTOVA (203 Czech Republic), Aneta ROZSYPALOVA (203 Czech Republic), Josef DVORAK (203 Czech Republic), Ondrej BROM (203 Czech Republic) and Bohuslav MELICHAR (203 Czech Republic)

Edition

Biomedical Papers, Olomouc: Palacky University, Olomouc, Palacky University, 2022, 1213-8118

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30204 Oncology

Country of publisher

Czech Republic

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 0.900

RIV identification code

RIV/00216224:14110/22:00128267

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.5507/bp.2020.055

UT WoS

000731338900001

Keywords in English

cabozantinib; metastases; renal cell carcinoma; toxicity

Abstract

V originále

Aim. The aim of this study was to retrospectively analyze treatment outcomes and tolerance in patients in whom cabozantinib was used after previous targeted therapy. Patients and Methods. Cabozantinib was administered in dose 60 mg/day, a subset of patients received initial dose of 40 mg/day. The treatment was administered until to progression or unacceptable toxicity. CT scans were assessed according to the RECIST 1.1 and toxicity of treatment was assessed based on the CTCAE (version 4). Kaplan-Meier analysis was used to calculate progression free survival (PFS) and overall survival (OS). We performed a multivariate analysis of risk factors for treatment outcomes (PFS, OS) by Cox regression analysis. All statistics were evaluated at the significance level alpha = 0.05. Results. 54 patients with metastatic renal cell carcinoma (mRCC) were evaluated. Median PFS in all patients treated with cabozantinib was 9.3 months (95% CI 5.3 - 13.3). One-year survival was 85.2% (95% CI 72.9 - 93.4%). Treatment response was observed in 45.9% of cases, including one complete remission. Cox regression analysis demonstrated that presence of subsequent treatment was the only factor with a significant effect on OS (P=0.008). Adverse events occurred in 88.9% of patients, grade 3 - 4 in 46.3%. Conclusion. The analysis of our cohort of patients treated with cabozantinib in the second or higher lines of treatment showed that cabozantinib represents an effective and safe therapy and contributes to longer survival of our mRCC patients

Citovat

RICHTER, Igor, Alexandr POPRACH, Anezka ZEMANKOVA, Tomas BUCHLER, Jiri BARTOS, Vladimir SAMAL, Hana STUDENTOVA, Aneta ROZSYPALOVA, Josef DVORAK, Ondrej BROM and Bohuslav MELICHAR. Patients with metastatic renal cell carcinoma treated with cabozantinib in the Czech Republic: analysis of four cancer centers. Biomedical Papers, Olomouc: Palacky University. Olomouc: Palacky University, 2022, vol. 166, No 1, p. 97-104. ISSN 1213-8118. Available from: https://dx.doi.org/10.5507/bp.2020.055.

@article{2249589,
   author = {Richter, Igor and Poprach, Alexandr and Zemankova, Anezka and Buchler, Tomas and Bartos, Jiri and Samal, Vladimir and Studentova, Hana and Rozsypalova, Aneta and Dvorak, Josef and Brom, Ondrej and Melichar, Bohuslav},
   article_location = {Olomouc},
   article_number = {1},
   doi = {http://dx.doi.org/10.5507/bp.2020.055},
   keywords = {cabozantinib; metastases; renal cell carcinoma; toxicity},
   language = {eng},
   issn = {1213-8118},
   journal = {Biomedical Papers, Olomouc: Palacky University},
   title = {Patients with metastatic renal cell carcinoma treated with cabozantinib in the Czech Republic: analysis of four cancer centers},
   url = {https://biomed.papers.upol.cz/artkey/bio-202201-0014_patients-with-metastatic-renal-cell-carcinoma-treated-with-cabozantinib-in-the-czech-republic-analysis-of-four.php},
   volume = {166},
   year = {2022}
}

TY  - JOUR
ID  - 2249589
AU  - Richter, Igor - Poprach, Alexandr - Zemankova, Anezka - Buchler, Tomas - Bartos, Jiri - Samal, Vladimir - Studentova, Hana - Rozsypalova, Aneta - Dvorak, Josef - Brom, Ondrej - Melichar, Bohuslav
PY  - 2022
TI  - Patients with metastatic renal cell carcinoma treated with cabozantinib in the Czech Republic: analysis of four cancer centers
JF  - Biomedical Papers, Olomouc: Palacky University
VL  - 166
IS  - 1
SP  - 97-104
EP  - 97-104
PB  - Palacky University
SN  - 12138118
KW  - cabozantinib
KW  - metastases
KW  - renal cell carcinoma
KW  - toxicity
UR  - https://biomed.papers.upol.cz/artkey/bio-202201-0014_patients-with-metastatic-renal-cell-carcinoma-treated-with-cabozantinib-in-the-czech-republic-analysis-of-four.php
N2  - Aim. The aim of this study was to retrospectively analyze treatment outcomes and tolerance in patients in whom cabozantinib was used after previous targeted therapy. Patients and Methods. Cabozantinib was administered in dose 60 mg/day, a subset of patients received initial dose of 40 mg/day. The treatment was administered until to progression or unacceptable toxicity. CT scans were assessed according to the RECIST 1.1 and toxicity of treatment was assessed based on the CTCAE (version 4). Kaplan-Meier analysis was used to calculate progression free survival (PFS) and overall survival (OS). We performed a multivariate analysis of risk factors for treatment outcomes (PFS, OS) by Cox regression analysis. All statistics were evaluated at the significance level alpha = 0.05. Results. 54 patients with metastatic renal cell carcinoma (mRCC) were evaluated. Median PFS in all patients treated with cabozantinib was 9.3 months (95% CI 5.3 - 13.3). One-year survival was 85.2% (95% CI 72.9 - 93.4%). Treatment response was observed in 45.9% of cases, including one complete remission. Cox regression analysis demonstrated that presence of subsequent treatment was the only factor with a significant effect on OS (P=0.008). Adverse events occurred in 88.9% of patients, grade 3 - 4 in 46.3%. Conclusion. The analysis of our cohort of patients treated with cabozantinib in the second or higher lines of treatment showed that cabozantinib represents an effective and safe therapy and contributes to longer survival of our mRCC patients
ER  -

RICHTER, Igor, Alexandr POPRACH, Anezka ZEMANKOVA, Tomas BUCHLER, Jiri BARTOS, Vladimir SAMAL, Hana STUDENTOVA, Aneta ROZSYPALOVA, Josef DVORAK, Ondrej BROM and Bohuslav MELICHAR. Patients with metastatic renal cell carcinoma treated with cabozantinib in the Czech Republic: analysis of four cancer centers. \textit{Biomedical Papers, Olomouc: Palacky University}. Olomouc: Palacky University, 2022, vol.~166, No~1, p.~97-104. ISSN~1213-8118. Available from: https://dx.doi.org/10.5507/bp.2020.055.

Detailed Information on Publication Record